Benefits for external project partners and companies

Knowledge-based, directed drug design

Providing drug candidates in a one-stop-shop concept

Bridging the gap between basic research and regulatory development

iCAIR® – translating research into drugs: Our services and expertise

iCAIR®: battling infection and resistance

These days, even a “simple” infection can become a deadly threat again. Bacteria keep developing new resistances to antibiotics, presenting the international medical community with a significant problem. There is a desperate need for new medications. The biggest hurdle in developing these new medications is getting them from the laboratory into clinical trials, bridging the gap from the discovery of new agents to their development by the pharmaceutical industry into potential medications.

In the project iCAIR® (International Consortium for Anti-Infective Research), researchers from Fraunhofer ITEM, the Hannover Medical School, Helmholtz Centre for Infection Research in Braunschweig, and Griffith University's Institute for Glycomics in Gold Coast, Australia, have teamed up to close this gap.

iCAIR®: News and projects

iCAIR® has delivered first results

On the way to inhalable drugs against  SARS-CoV-2.

Press release: iCAIR® uses synergies to develop medications against SARS-CoV-2

May 07, 2020


Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0


Press release: Pancreas drug nafamostat an option for COVID-19

July 31, 2020

Fraunhofer Podcast about iCAIR®


Press release: iCAIR is breaking new ground in the development of antiviral drugs

May 29, 2019


Press release: Fighting infections and resistances

December 04, 2019